

## Contents

<b>Foreword</b>	xv		
<b>Preface</b>	xvii		
<b>About the Companion Website</b>	xix		
<b>1 Introduction to Advanced Chemical Biology</b>	1		
<i>Howard C. Hang, Matthew R. Pratt, and Jennifer A. Prescher</i>			
1.1	Introduction	1	
1.2	Enabled by Synthetic and Physical Organic Chemistry	1	
1.3	Guided by Biochemistry and Structural Biology	3	
1.4	Enhanced by Engineering and Evolution	3	
1.5	Expanded by Analytical Chemistry and “Omics” Technologies	4	
1.6	Impact on Biological Discovery and Drug Development	5	
1.7	Outlook	5	
	References	6	
<b>2 DNA Function, Synthesis, and Engineering</b>	9		
<i>Aneesh T. Veetil and Yamuna Krishnan</i>			
2.1	Introduction: A Historical Perspective	9	
2.1.1	The Structure of DNA	9	
2.2	New Nucleobases and Unusual DNA Conformations	11	
2.2.1	G-Quadruplex DNA Structures	11	
2.2.2	Circular DNA Structures	11	
2.2.3	Aptamers	11	
2.2.4	Other Nucleobases	12	
2.3	The Modern Synthesis of DNA	13	
2.3.1	Solid-Phase DNA Synthesis	13	
2.3.2	Backbone-Modified Oligonucleotides	15	
2.3.2.1	Peptide Nucleic Acids (PNAs)	16	
2.3.2.2	Morpholino Nucleic Acids	16	
2.4	DNA Sequencing	16	
2.4.1	Modern Methods to Sequence DNA	16	
2.4.1.1	Sequencing by Synthesis (SBS)	17	
2.4.1.2	Third-Generation DNA Sequencing	17	
2.5	DNA Engineering	18	
2.5.1	DNA Nanotechnology	18	
2.5.2	DNA-Templated Nanoparticle Assembly	19	
2.5.3	DNA Nanomachines	20	
2.5.4	DNA Nanotechnology for Biology	20	
2.5.5	DNA-Based Organelle Mapping Technology	20	
2.5.6	DNA-Based Technologies for the Detection of Endogenous Nucleic Acids and Proteins	22	
2.5.6.1	Fluorescence <i>In Situ</i> Hybridization (FISH)	22	
2.5.6.2	DNA-Barcoded Antibodies for Spatial Detection of Proteins	22	
2.5.7	DNA-Based Super Resolution Imaging	22	
2.5.8	DNA-Encoded Libraries (DEL)	23	
2.5.9	Digital Data Storage Using DNA	23	
2.6	Tools for Engineering DNA	24	
2.7	Summary and Future Outlook	25	
	Acknowledgments	25	
	Questions	25	
	References	26	
<b>3 Chemical Approaches to Genome Integrity</b>	31		
<i>Elizabeth R. Lotsof, Savannah G. Conlon, and Sheila S. David</i>			
3.1	Introduction and Historical Perspective	31	
3.2	Types of DNA Damage	32	
3.2.1	Damage to Nucleobase	32	
3.2.1.1	Oxidation	32	
3.2.1.2	Alkylation	33	
3.2.1.3	Depurination/Depyrimidination	35	
3.2.1.4	Deamination	35	
3.2.1.5	DNA Mismatches	35	
3.2.1.6	DNA Crosslinks	35	
3.2.2	Damage to Sugar	36	
3.2.3	Damage to Phosphate Backbone	36	
3.3	Types of DNA Repair	36	
3.3.1	Direct Repair	36	
3.3.2	Base Excision Repair	38	
3.3.3	Nucleotide Excision Repair	38	
3.3.4	Mismatch Repair	39	

3.3.5	Double-Strand Break and Interstrand Crosslink Repair	39	4.5	Identification and Engineering of Functional RNAs	62
3.4	Identification of Sites of DNA Damage and Modification	40	4.5.1	Aptamers	62
3.4.1	Traditional Methods for Damage Detection	40	4.5.2	Riboswitches	63
3.4.2	Searching for Hotspots of Oxidative Damage – An OG Story	41	4.5.3	Ribozymes	63
3.4.3	Sequencing for Bulky Adducts – Cisplatin and Pyrimidine Dimers	41	4.5.4	Genetically Encoded Tags to Label RNA	64
3.4.4	Sequencing for AP Site and Strand Breaks	44	4.5.5	RNA-Based Therapeutics	64
3.5	Assays that Allow for Monitoring of the Repair of DNA Damage in Cellular Contexts	44	4.6	The Sequencing of RNA	64
3.5.1	Lesion Reporter Assays to Monitor Base Excision Repair	45	4.6.1	Reverse Transcription of RNA	65
3.5.2	Leveraging Cell-Based Reporter Assays to Assess Impact of DNA Lesions on Replication and Transcription	47	4.6.2	Long-Read and Direct RNA Sequencing	65
3.5.3	Plasmid Reporters Monitoring Several DNA Repair Pathways Simultaneously	47	4.6.3	Extensions and Alternative Approaches to RNA-seq	66
3.5.4	Highly Sensitive Fluorescent DNA Repair Probes for Clinical Diagnostics and Imaging in Cells	48	4.7	The Chemical Probing of RNA Structure	66
3.6	Summary and Future Outlook	48	4.7.1	In-Line Probing of RNA Conformation	67
	Acknowledgments	48	4.7.2	Reagents for Chemical Probing of RNA Conformation and Base-Pairing	67
	Exam Questions	48	4.7.3	Reagents for Probing Solvent Accessibility, Tertiary Structure, and Higher Order Interactions	68
	References	50	4.8	Summary and Future Outlook	69
<b>4</b>	<b>RNA Function, Synthesis, and Probing</b>	<b>55</b>		Questions	69
	<i>Andreas Pintado-Urbanc and Matthew D. Simon</i>			References	69
4.1	Introduction	55	<b>5</b>	<b>Chemical Approaches to Transcription and RNA Regulation</b>	
4.2	The Principles of RNA Chemistry	56		<i>In Vivo</i>	75
4.2.1	The Impact of a 2'-Hydroxyl on Nucleic Acid Chemistry	56		<i>Tong Wu and Chuan He</i>	
4.2.2	RNA Bases and Base-Pairing	56	5.1	Introduction/Historical Perspective	75
4.2.3	RNA Secondary Structure	58	5.2	Core Concepts/Landmark Studies	75
4.2.4	RNA Tertiary Structures and the Ribosome	58	5.2.1	Transcription Regulation in Eukaryotes	75
4.3	Synthesis of RNA	58	5.3	Transcription Regulation by Chemical Targeting of DNA and the Core Transcription Machinery	76
4.3.1	Chemical Synthesis	58	5.3.1	Cell-Permeable DNA-Targeting Small Molecules	76
4.3.2	<i>In Vitro</i> Transcription	59	5.3.2	Targeting Transcription by Nucleic Acids and Their Analogs	79
4.4	Labeling of RNA	60	5.3.3	Small-Molecule Inhibitors of the Transcription Machinery	80
4.4.1	Introducing Modifications Through Chemical Synthesis of RNA	60	5.4	Chemical Regulation of Transcription via Targeting of Epigenetic Elements	81
4.4.2	Using Ligation to Introduce Chemical Modifications into RNA	60	5.4.1	Transcription Regulation Through Targeting of Histone Modifications	81
4.4.3	Incorporation of Modified Bases into RNA Using IVT	61	5.4.2	DNA Methylation and Small Molecules Targeting DNA Modifications	83
4.4.4	Approaches to 3'-End Label RNA	62	5.5	Chemical Approaches to Target Post-Transcriptional RNA Metabolism	86
4.4.5	Approaches to 5'-End Label RNA	62	5.5.1	Post-Transcriptional RNA Metabolism	86
			5.5.2	Regulating RNA Function by Direct RNA Binders	89
			5.5.3	Regulating RNA Function by Targeting RNA-Binding (Effector) Proteins	91

5.6	Summary and Future Outlook	91	7.2.1	SPPS Is Optimized for Stepwise Efficiency	135
	Questions	92	7.2.2	N <sup>α</sup> -protecting Groups Ensure Single Coupling of the Incoming Amino Acid	136
	References	92	7.2.3	Plastic Resins Are Used During SPPS	138
<b>6</b>	<b>Chemical Biology of Genome Engineering</b>	99	7.2.4	Temporary Masking of Reactive Side Chains Is Necessary During SPPS	138
	<i>Carlos A. Vasquez and Alexis C. Komor</i>		7.2.5	Peptide Bonds Are Synthesized by a Condensation Reaction Mediated by a Stoichiometric Coupling Agent	140
6.1	Introduction to Genome Editing	99	7.3	Secondary and Tertiary Structures of Amino Acids	142
6.2	Early Genetic Engineering Experiments: Chemical Mutagenesis, Gene Transfer, and Gene Targeting	100	7.3.1	Peptide Backbone Conformations	142
6.2.1	Chemical Mutagenesis Methods	100	7.3.2	Biophysical Determinants of Helix Folding and Design of $\alpha$ -Helix Mimics	143
6.2.2	Gene Transfer	101	7.3.3	$\beta$ -Strand and $\beta$ -Sheet Mimics	145
6.2.3	Gene Targeting	102	7.3.4	Protein Tertiary Structure Mimics	147
6.3	Improving Precision and Programmability with Double-Stranded DNA Breaks	103	7.3.4.1	$\beta$ -Sheet and $\beta$ -Hairpin Mimics	147
6.3.1	The Development of Double-Stranded Break-Reliant Genome Editing Technologies	103	7.3.5	Helical Tertiary Structure Mimics	149
6.3.2	Repair of Double-Stranded DNA Breaks in Mammalian Cells	104	7.4	Conformationally Defined Peptides as Modulators of Protein Interactions	150
6.3.3	Meganucleases	105	7.4.1	Peptide Therapeutics	151
6.3.4	Zinc Finger Nucleases (ZFNs)	106	7.5	Summary and Future Outlook	157
6.3.5	Transcription Activator–Like Effector Nucleases (TALENs)	108		Questions	157
6.4	The Golden Age of Genome Engineering: CRISPR-Based Genome Editing Technologies	108		References	158
6.4.1	Introduction	108	<b>8</b>	<b>Protein Synthesis and Engineering</b>	167
6.4.2	CRISPR-Cas9	109		<i>Matthew R. Pratt and Tom W. Muir</i>	
6.4.3	Programmability Improvements	111	8.1	Introduction/Historical Perspective	167
6.4.4	Efficiency Improvements	113	8.2	Core Concepts/Landmark Studies	170
6.4.5	Specificity Improvements	113	8.2.1	Cysteine-thioester-Based Ligations: Making the Pieces	170
6.4.6	Precision Improvements	115	8.2.1.1	C-terminal Pieces: Chemical Synthesis of N-terminal Cysteine Peptides	170
6.4.7	Epigenome Editing	115	8.2.1.2	C-terminal Pieces: Recombinant Expression of N-terminal Cysteine Peptides/Proteins	170
6.5	Non-DSB-Reliant Genome Editing Technologies	116	8.2.1.3	N-terminal Pieces: Chemical Synthesis of Thioester-Containing Peptides	171
6.5.1	Base Editing	116	8.2.1.4	N-terminal Pieces: Recombinant Expression of Thioester-Containing Proteins	172
6.5.2	Prime Editing	119	8.2.1.5	Internal Fragments: Preparation of Cysteine and Thioester-Containing Peptides/Proteins	172
6.6	Gene Editing Methods for Spatial and Temporal Control	119	8.2.2	Adding More Pieces: Moving Beyond Thioester/Cysteine Ligations	173
6.7	Ethical Implications, Summary, and Future Outlook	121	8.2.2.1	Desulfurization	174
	Questions	123	8.2.2.2	Auxiliaries	174
	References	123	8.2.2.3	Other Ligation Chemistries	176
<b>7</b>	<b>Peptide Synthesis and Engineering</b>	135	8.3	Putting the Pieces Together: Practical Considerations for Ligation Reactions	178
	<i>Gordon C. Brown and Paramjit S. Arora</i>				
7.1	Introduction	135			
7.2	Peptide Synthesis	135			

- 8.4 Protein Trans-splicing 178
- 8.5 Examples of Protein Synthesis 179
  - 8.5.1 Post-Translational Modifications 179
    - 8.5.1.1 Cell Signaling 179
    - 8.5.1.2 Chromatin 181
    - 8.5.1.3 Amyloid-Forming Proteins 181
  - 8.5.2 Chemical and Biophysical Probes 182
    - 8.5.2.1 Backbone Modifications 182
    - 8.5.2.2 Segmental Isotopic Labeling 182
  - 8.5.3 Mirror Image Proteins 184
    - 8.5.3.1 Racemic Crystallography 184
    - 8.5.3.2 Mirror Image Display 184
  - 8.5.4 Protein Ligation in Living Systems 184
  - 8.5.5 Potential Therapeutic Applications 184
- 8.6 Summary and Future Outlook 185
  - Questions 185
  - References 186
- 9 Directed Evolution for Chemical Biology 193**  
*Pu Xue, Fang Guo, Linzixuan Zhang, and Huimin Zhao*
  - 9.1 Introduction 193
  - 9.2 Methodologies 195
    - 9.2.1 Directed Evolution at the Protein Level 195
      - 9.2.1.1 Random Mutagenesis 195
      - 9.2.1.2 Gene Recombination 195
      - 9.2.1.3 Semi-Rational Design 197
    - 9.2.2 Directed Evolution at the Pathway Level 198
      - 9.2.2.1 Directed Evolution of a Single Enzyme in a Pathway 198
      - 9.2.2.2 Directed Evolution of an Entire Pathway 199
    - 9.2.3 Directed Evolution at the Genome Level 199
      - 9.2.3.1 Adaptive Laboratory Evolution 199
      - 9.2.3.2 Genome-Scale Engineering Strategies 200
    - 9.2.4 Continuous Directed Evolution 200
    - 9.2.5 Screening or Selection Methods 201
      - 9.2.5.1 Selection-Based Techniques 202
      - 9.2.5.2 Screening-Based Techniques 203
  - 9.3 Case Studies 203
    - 9.3.1 Directed Evolution of a Glyphosate *N*-Acetyltransferase 203
    - 9.3.2 Directed Evolution of a Transaminase for Sitagliptin Manufacture 207
    - 9.3.3 Directed Evolution of a Cytokine Using DNA Family Shuffling 208
    - 9.3.4 Efficient Proximity Labeling in Living Cells and Organisms with TurboID 210
    - 9.3.5 Biocatalytic Cascade Evolution for Manufacturing Islatravir 211
  - 9.3.6 A Multi-Functional Genome-Wide CRISPR System 212
  - 9.4 Future Perspectives and Conclusion 212
    - Acknowledgments 213
    - Questions 213
    - References 214
- 10 Chemical Biology of Cellular Metabolism 221**  
*Peter C. Gray and Alan Saghatelian*
  - 10.1 Introduction/Historical Perspective 221
  - 10.2 Metabolite Detection and Quantitation 223
    - 10.2.1 Shotgun Metabolomics 223
    - 10.2.2 Targeted Metabolomics 225
    - 10.2.3 Metabolite Flux Analysis 225
    - 10.2.4 Untargeted Metabolomics 227
    - 10.2.5 Discovering Structurally Novel Metabolites 228
  - 10.3 Metabolite Imaging and Sensing 229
    - 10.3.1 Mass Spectrometry Imaging 229
    - 10.3.2 Chemical Probes for Metabolite Imaging 230
    - 10.3.3 Protein and RNA Metabolite Sensors 232
  - 10.4 Perturbation of Metabolite Levels 234
    - 10.4.1 Small-Molecule Inhibitors and Drugs of Metabolism 234
    - 10.4.2 Enzymatic Perturbation of Metabolism 235
  - 10.5 The Impact of Chemical Biology in Disease and Drug Discovery 236
  - 10.6 Summary and Future Outlook 237
    - Questions 238
    - References 238
- 11 Chemical Biology of Lipids 243**  
*Scotland Farley, Alix Thomas, Aurélien Laguerre, and Carsten Schultz*
  - 11.1 Introduction 243
  - 11.2 Identification of Bulk Lipids 245
    - 11.2.1 Lipidomics by Mass Spectrometry 245
    - 11.2.2 Lipid Analysis by Thin-Layer Chromatography 247
  - 11.3 Fixing Lipids in Subcellular Space 247
    - 11.3.1 Protein-Based Techniques to Localize Lipids 248
    - 11.3.2 Mass Spectrometry Imaging of Lipids 249
    - 11.3.3 Lipid Detection Using Modified Lipids as Probes 249
  - 11.4 Tracing Individual Lipids via In Cellulo Click Chemistry 250
    - 11.4.1 Alkyne/Azide-Modified Lipids and Click Chemistry 251
    - 11.4.2 Bifunctional Lipid Derivatives 251

11.5	Tools to Elucidate Lipid Signaling	253	13	<b>Chemical Glycobiology</b>	295
11.5.1	Metabolic Machinery as a Chemical Tool: the Advantage of Chemical Dimerizers	253		<i>Amélie M. Joffrin, Alexander W. Sorum, and Linda C. Hsieh-Wilson</i>	
11.5.2	Releasing Bioactive Lipids with Light	255	13.1	Introduction	295
11.6	A Comprehensive View of Protein–Lipid Interactions	256	13.2	Total Chemical Synthesis of Structurally Defined Glycans	297
11.6.1	Trifunctional Lipids	256	13.3	Enzymatic and Chemoenzymatic Synthesis of Glycans	300
11.6.2	Lipid–Protein Interactome	258	13.4	Programmable and Automated Glycan Synthesis	302
11.7	Summary and Future Outlook	258	13.5	Synthesis of Glycopeptides and Glycoproteins	303
	Questions	259	13.6	Glycan Microarrays	305
	References	259	13.7	Chemical Tagging and Remodeling of Cellular Glycans	306
<b>12</b>	<b>Protein Posttranslational Modifications</b>	267	13.8	Inhibitors of Glycan-Processing Enzymes and Glycan Binding Proteins	310
	<i>Sam Whedon and Philip A. Cole</i>		13.9	Glycan-Targeted Therapeutics	313
12.1	Introduction	267	13.10	Summary and Future Outlook	316
12.2	Functional Impacts of PTMs	268		Questions	317
12.3	Evolution and PTMs	270		References	317
12.4	Major Classes of PTMs	270	<b>14</b>	<b>The Chemical and Enzymatic Modification of Proteins</b>	329
12.4.1	Phosphorylation	270		<i>Nicholas S. Dolan, Johnathan C. Maza, Alexandra V. Ramsey, and Matthew B. Francis</i>	
12.4.2	Acetylation	272	14.1	Introduction	329
12.4.3	Ubiquitination	273	14.2	General Considerations	329
12.4.4	Methylation	275	14.3	Lysine Modification	330
12.4.5	Glycosylation	275	14.4	Aspartic Acid, Glutamic Acid, and C-Terminal Carboxylate Modification	333
12.4.6	Lipidation of Proteins	278	14.5	Tyrosine Modification	334
12.4.7	Oxidation of Proteins	278	14.6	Cysteine Modification	337
12.4.8	Miscellaneous Modifications	278	14.7	Methionine Modification	340
12.5	Writers and Erasers	280	14.8	Tryptophan Modification	341
12.5.1	Protein Kinases and Phosphatases	280	14.9	Histidine Modification	343
12.5.2	Acetyltransferases and Deacetylases	280	14.10	Serine and Threonine Modification	344
12.5.3	Ubiquitin Ligases and Deubiquitinases	281	14.11	N-Terminal Modification	344
12.5.4	Methylation and Demethylases	281	14.12	Enzymatic Approaches to Modifying Proteins	347
12.5.5	Glycosyltransferases and Glycosidases	282	14.12.1	Transpeptidases	347
12.5.6	Lipid Transferase and Hydrolases	282	14.12.2	Ligases	348
12.6	Strategies for the Study of PTMs	283	14.12.3	Activating Enzymes	349
12.6.1	Mutagenesis	283	14.13	Summary and Future Outlook	350
12.6.2	Genetic Codon Expansion	283		Questions	350
12.6.3	Small-Molecule Probes and Chemical Complementarity	283		References	352
12.6.4	Chemical Ligation	284	<b>15</b>	<b>Genetic Code Expansion</b>	359
12.6.5	Protein Microarrays	284		<i>Peng R. Chen, Shixian Lin, and Jie P. Li</i>	
12.7	Protein PTMs in Diseases	284	15.1	Introduction	359
12.7.1	Protein Kinases and Diseases	285	15.2	Genetic Code Expansion Through Directed Evolution of aaRS/tRNA Pairs	359
12.7.2	Lys Acetylation and Cutaneous T Cell Lymphoma	285			
12.7.3	Ubiquitination	285			
12.8	Summary	286			
	Questions	286			
	References	287			

15.2.1	The Development of the Mj.TyrRS-tRNA Based GCE System	360	16.6	Cu-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) of Azides and Terminal Alkynes	393
15.2.2	The Development of Additional aaRS/tRNA-Based GCE System	362	16.7	Strain-Promoted [3+2] Azide-Alkyne Cycloaddition (SPAAC) of Azides and Cyclooctynes	395
15.2.3	The PylRS-tRNA Pair as a “one-stop-shop” GCE System	362	16.8	The Tetrazine Ligation: Rapid Bioorthogonal Inverse Electron-Demand Diels–Alder Reactions	396
15.2.4	Genetic Code Expansion in Multicellular Organisms	363	16.9	Other Bioorthogonal Ligations	398
15.3	GCE with Genome Recoding Strains and/or Unnatural Codons	364	16.10	Light-Activated Bioorthogonal Reactions	399
15.3.1	GCE with Genome Recoding Strains	364	16.11	Bioorthogonal Uncaging and Cleavage Reactions	400
15.3.2	GCE with Four-Base Codons Using Orthogonal Ribosome	366	16.12	Mutually Orthogonal Bioorthogonal Reactions	401
15.3.3	Genetic Code Expansion with Unnatural Base Pairs	366	16.13	Fluorogenic Bioorthogonal Reagents	402
15.4	GCE-based Applications	366	16.14	Applications of Bioorthogonal Chemistry	403
15.4.1	Site-Specific Posttranslational Modifications (PTMs)	367	16.14.1	Bioorthogonal Non-canonical Amino Acid Tagging (BONCAT)	403
15.4.2	New “Physical” Property Empowered by ncAAs	369	16.14.2	<i>In Vivo</i> Imaging of Glycans	404
15.4.3	New Chemical Reactivity Derived from ncAA and Their Unique Applications	369	16.14.3	Therapeutic Applications of Bioorthogonal Chemistry	404
15.4.4	Control of Protein Activation	372	16.15	Summary and Future Outlook	406
15.5	Therapeutic Conjugates	374		Questions	406
15.6	Live-Attenuated Virus and Other Genetically Modified Vaccines	375		References	407
15.7	Summary and Future Outlook	376			
15.7.1	Improving the Efficiency	376	<b>17</b>	<b>Cellular Imaging</b>	415
15.7.2	Expanding the Applications	376		<i>Amy E. Palmer and Luke D. Lavis</i>	
15.7.3	Exploring the Therapeutic Potential	377	17.1	Introduction	415
	Questions	377	17.1.1	History	415
	References	377	17.1.2	Light and Fluorescence	417
<b>16</b>	<b>Bioorthogonal Chemistry</b>	387	17.2	Small-Molecule Fluorophores	417
	<i>Jeremy Baskin and Pamela Chang</i>		17.2.1	Background	417
16.1	Introduction and Historical Perspective	387	17.2.2	Pyrenes and Coumarin Fluorophores	417
16.2	Key Concepts: Bioorthogonality and Bioorthogonal Reactions, Click Chemistry, and the Bioorthogonal Metabolic Reporter Strategy	388	17.2.3	BODIPY Dyes	418
16.2.1	Bioorthogonality and Bioorthogonal Reactions	388	17.2.4	Fluoresceins and Rhodamines	418
16.2.2	Click Chemistry	388	17.2.5	Phenoxazine and Cyanine Dyes	419
16.2.3	The Bioorthogonal Metabolic Reporter Strategy	389	17.2.6	Use as Biomolecule Labels	419
16.3	The Beginnings of Bioorthogonal Chemistry: Oxime and Hydrazone Formation	390	17.2.7	Use as Cellular Stains	419
16.4	The Azide as a Bioorthogonal Handle	391	17.2.8	Fluorescent Indicators	420
16.5	The Staudinger Ligation of Azides and Phosphines	392	17.2.9	Enzyme Substrates	421
			17.3	Fluorescent Proteins	421
			17.3.1	Background	421
			17.3.2	General Considerations of Fluorescent Proteins	421
			17.3.3	Fluorescent Proteins as Biomolecule Labels and “Stains”	422
			17.3.4	Fluorescent Proteins as Sensors	423
			17.3.5	Fluorescent Proteins as Enzyme Substrates	423

17.4	Hybrid Small-Molecule-Protein Systems	424	19	<b>Chemical Biology of Metals</b>	459
17.4.1	Background	424		<i>Eva J. Ge, Patricia De La Torre, and Christopher J. Chang</i>	
17.4.2	Labels	425	19.1	Introduction	459
17.4.3	Sensors	426	19.2	Metals and the Inorganic Foundations of Life	459
17.5	Landmark Study I: Harnessing Photosensitive Fluorophores	426	19.2.1	Metal Complexes are Lewis Acid-Base Complexes	459
17.5.1	Background	426	19.2.2	Crystal Field Theory Enables Bonding Analysis from Molecular Shape and d Orbitals	460
17.5.2	Super-Resolution Microscopy	426	19.2.3	Hard Soft Acid Base Theory Defines Metal-Ligand Preferences	462
17.6	Landmark Study II: Ca <sup>2+</sup> Imaging	427	19.3	Non-Redox Roles for Metals in Biology: Structure and Lewis Acid Catalysis	462
17.6.1	Background	427	19.3.1	Metals for Stabilizing Nucleic Acid Structure	463
17.6.2	Small-Molecule Ca <sup>2+</sup> Indicators	427	19.3.2	Metals as Protein Structural Units: Zinc Finger and EF Hand Motifs	463
17.6.3	Genetically Encoded Ca <sup>2+</sup> Indicators	428	19.3.3	Metals as Lewis Acid Catalysts: Metallohydrolases	464
17.6.4	Genetically Encoded Indicators for <i>In Vivo</i> Imaging	428	19.4	Redox Chemistry: Oxygen Transport and Electron Transfer Proteins	464
17.7	Summary and Future Outlook	430	19.4.1	Oxygen Transport Requires Redox-Active Metal Binding	465
	Questions	430	19.4.2	Marcus Theory and Electron Transfer Proteins	465
	References	430	19.5	Redox Chemistry: Metalloenzymes for Redox Catalysis at Oxygen, Nitrogen, and Carbon	467
18	<b><i>In Vivo</i> Imaging</b>	435	19.5.1	Oxygen Evolution in Photosynthesis: Photosystem II	467
	<i>Zi Yao and Jennifer A. Prescher</i>		19.5.2	Oxygen Reduction: Respiration with Cytochrome <i>c</i> Oxidase	467
18.1	Introduction	435	19.5.3	Oxygen Catalysis: Heme and Non-Heme Iron-Dependent Oxidations	468
18.2	Basic Concepts for Imaging <i>In Vivo</i>	436	19.5.4	Nitrogen Cycle: Nitrogenases and Nitrate/Nitrite Reductases	469
18.3	The Imaging Toolbox: Probes for Imaging Cellular and Molecular Features	438	19.5.5	Bioorganometallic Chemistry: Carbon Cycling and Vitamin B12	469
18.3.1	“Always On” Probes	439	19.6	Metals in Medicine: Metallotargets, Metallodrugs, and Metal-Based Imaging Agents	470
18.3.2	“Turn-On” (Activatable) Probes	439	19.7	Emerging Areas for Metals in Biology: Transition Metal Signaling and Metalloallostery	472
18.3.3	Genetically Encoded Probes	439	19.8	Chemical Tools to Study Metal Biology	472
18.4	Molecular Imaging Across the Electromagnetic Spectrum	440	19.9	Summary and Future Outlook	475
18.4.1	Imaging with X-rays (CT)	440		Questions	475
18.4.2	Imaging with Sound (US)	440		References	476
18.4.3	Imaging with Radio Waves (MRI)	441			
18.4.4	Imaging with Radionuclides (PET/SPECT)	442			
18.4.5	Imaging with Optical Light (Fluorescence/Bioluminescence)	444			
18.4.5.1	Targeted Fluorophores and Fluorescent Materials	445			
18.4.5.2	Activatable Probes	445			
18.4.5.3	Genetically Encoded Fluorescent Probes	445			
18.4.5.4	Genetically Encoded Bioluminescent Proteins (Luciferases)	447			
18.4.5.5	Engineered Probes for Sensing Metabolites and Molecular Features	447			
18.5	Multimodality Imaging and Combination Probes	449			
18.6	Emerging Areas in Molecular Imaging	450			
18.7	Summary and Future Outlook	450			
	Questions	451			
	References	451			

<b>20</b>	<b>Redox Chemical Biology</b> 481	<b>21.3</b>	<b>Summary and Future Outlook</b> 518
	<i>Yunlong Shi and Kate S. Carroll</i>		Questions 518
20.1	Introduction 481		References 519
20.2	Activity-Based Detection of Cysteine Modifications 484	<b>22</b>	<b>Chemical Genetics</b> 527
20.3	Indirect Profiling of Cysteine Oxidation 484		<i>Michael S. Cohen</i>
20.4	Direct Profiling of Cysteine OxiPTMs with Chemoselective Probes 486	22.1	Introduction 527
20.4.1	Profiling Protein Sulfenic Acids (–SOH) 486	22.2	AS-Protein – Orthogonal Molecular Glues 528
20.4.1.1	Sulfenic Acid Probes – A Historical Perspective 486	22.3	AS-Enzyme – Orthogonal Substrate Pairs 532
20.4.1.2	Chemical Models for the Assessment of Sulfenic Acid Probes 486	22.3.1	Protein Kinases 532
20.4.1.3	Selectivity of Chemical Probes for Sulfenic Acids 486	22.3.2	Protein Methyltransferases 535
20.4.1.4	Quantification of Protein Sulfenic Acids 489	22.3.3	Protein Lysine Acetyltransferases 538
20.4.1.5	Application of Sulfenic Acid Probes 492	22.3.4	PARPs 539
20.4.2	Profiling Protein Sulfenic Acids (–SO <sub>2</sub> H) 492	22.3.5	Glycosyltransferases 542
20.4.3	Profiling Protein Persulfides (–SSH) 493	22.3.6	PTM Erasers: Lysine Demethylases 544
20.5	Probes and Biosensors for Reactive Oxygen Species in Cells 494	22.3.7	Beyond PTM Enzymes 544
20.6	Conclusions and Outlook 496	22.4	AS-Enzyme – Orthogonal Inhibitor Pairs 547
	Questions 496	22.4.1	Protein Kinases 547
	References 497	22.4.2	Other Enzymes 549
<b>21</b>	<b>Activity-Based Protein Profiling</b> 503	22.5	Final Thoughts 549
	<i>William H. Parsons and Benjamin F. Cravatt</i>	22.5.1	Beyond Bump–Hole 549
21.1	Introduction/Historical Perspective 503		Questions 550
21.2	Core Concepts/Landmark Studies 504		References 550
21.2.1	Probe Design 504	<b>23</b>	<b>Natural Product Discovery</b> 555
21.2.1.1	Reactive Groups 504		<i>Mohammad R. Seyedsayamdost, Brett C. Covington, Yifan Zhang, and Yuchen Li</i>
21.2.1.2	Reporter Tags 507	23.1	Introduction and Definitions 555
21.2.1.3	Recognition Group/Linker 508	23.2	Key Concept: Natural Products are Genetically Encoded 556
21.2.2	Detection Methods 509	23.3	Key Concept: Structural Differences Between Natural Products and Synthetic Drugs 558
21.2.2.1	Gel-Based Analysis 509	23.4	Key Concept: Target Specificity and Latent Reactivity 559
21.2.2.2	Fluorescence Polarization 510	23.5	Key Concept: Natural Product Discovery and Activity-Guided Fractionation 561
21.2.2.3	Imaging of Proteins in Cells and Organisms 511	23.6	Key Concept: Cryptic Biosynthetic Gene Clusters 562
21.2.2.4	Quantitative Proteomics by Mass Spectrometry 511	23.7	Landmark Studies: Penicillin and the Golden Age of Antibiotic Discovery 563
21.2.3	Common Applications 512	23.8	Landmark Studies: Activating Silent Biosynthetic Gene Clusters 565
21.2.3.1	Profiling Protein Activity and Amino Acid Reactivity in Biological Systems of Interest 513	23.8.1	Manipulation of Culture Conditions 565
21.2.3.2	Competitive ABPP for Ligand Discovery and Optimization 513	23.8.2	Classical Genetics 566
21.2.3.3	Target Identification for Ligands 515	23.8.3	Chemical Genetics 567
21.2.3.4	Assignment of Enzyme Function 516	23.8.4	Heterologous Expression 568
21.2.3.5	Visualizing Enzyme Localization and Activity in Living Cells and Organisms 517	23.9	Summary and Outlook 569



<b>24</b>	<b>Natural Product Biosynthesis</b>	<b>575</b>			
	<i>Eun Bin Go and Yi Tang</i>				
24.1	Introduction	575	25.5.2	Substrate Analogue PG Probes	612
24.2	Peptide Natural Products	577	25.6	Labeling Glycan Cell Envelope Components	613
24.2.1	Ribosomally Synthesized and Post-translationally Modified Peptides (RiPPs)	577	25.6.1	Diversity and Function of Bacterial Polysaccharides	613
24.2.2	Non-ribosomal Peptides	579	25.6.2	Probes of Bacterial Glycans	614
24.3	Polyketide Natural Products	582	25.6.3	Probes of LPS: AzKdo	615
24.3.1	Bacterial Type-I Polyketides	584	25.6.4	Labeling Mycobacterial Glycans	615
24.3.2	Bacterial Type-II Polyketides	586	25.6.5	Trehalose Analogs	616
24.4	Terpene Natural Products	588	25.6.6	Imaging Probes	616
24.5	Hybrid and Unnatural Natural Products	591	25.6.7	Fluorogenic Probes	617
24.6	Summary and Future Outlook	592	25.7	Chemical Probes Applied to the Microbiome	617
	Acknowledgment	592	25.7.1	Microbiome: Looking Forward	618
	Questions	593	25.8	Summary and Future Outlook	619
	References	594		Questions	619
				References	620
<b>25</b>	<b>Chemical Microbiology</b>	<b>597</b>	<b>26</b>	<b>Chemical Approaches to Analyze Biological Mechanisms and Overcome Resistance to Therapeutics</b>	<b>629</b>
	<i>Victoria M. Marando, Stephanie R. Smelyansky, Daria E. Kim, and Laura L. Kiessling</i>			<i>Rudolf Pisa, Tommaso Cupido, and Tarun M. Kapoor</i>	
25.1	Introduction and History	597	26.1	Introduction	629
25.2	Cell Envelope Structure and Biosynthesis	598	26.2	Using Chemical Inhibitors as Tools to Probe Cellular Processes	630
25.2.1	Bacterial Cell Structure	598	26.3	Using Resistance to Characterize Chemical Inhibitors	632
25.3	Chemical and Chemoenzymatic Synthesis for Pathway Elucidation	600	26.4	Crash-Testing Drugs	633
25.3.1	Peptidoglycan (PG) Biosynthesis	600	26.5	RADD – Resistance Analysis During Design	635
25.3.1.1	Reconstructing the Steps in PG Biosynthesis Using Defined Substrates	600	26.6	Designing Inhibitors with Distinct Binding Modes	636
25.3.1.2	Accessing Lipids I and II	602	26.7	Addressing Drug Resistance with Targeted Protein Degradation	639
25.3.2	Cell Envelope Components Beyond Peptidoglycan	603	26.8	Overcoming Resistance by Using Combinations of Drugs	640
25.3.2.1	Gram-Negative Lipopolysaccharides	603	26.9	Conclusions	641
25.3.2.2	Wall Teichoic Acid Biosynthesis	605		Questions	641
25.3.2.3	Mycobacterial Galactan	605		References	642
25.4	The Chemical Biology of Antibiotic Action	607	<b>27</b>	<b>Chemical Developmental Biology</b>	<b>647</b>
25.4.1	PG Assembly Is Targeted by Diverse Antibiotics	607		<i>James K. Chen</i>	
25.4.2	Penicillin and Other Antibiotics Induce Dominant-Negative Effects	609	27.1	Introduction	647
25.4.3	Identifying Inhibitors of Essential Enzymes Is Not Enough	609	27.2	Small-Molecule Teratogens	648
25.4.4	Identifying Attributes for Compound Uptake in Bacteria	610	27.2.1	Cyclopamine	648
25.5	Chemical Biology Strategies for Imaging PG Assembly and Remodeling	610	27.2.2	Thalidomide	650
25.5.1	Antibiotic-Based PG Probes	611	27.3	Optochemical and Optogenetic Probes	653
25.5.1.1	Antibiotics that Bind PG Intermediates	611	27.3.1	Optochemical Control of Gene Expression	653
25.5.1.2	Probes from Antibiotics that Act on Enzymes that Generate PG	612			

27.3.2	Optogenetic Control of Cell Signaling	657	29.3	Visualization	708
27.4	Lineage Tracing Tools	660	29.3.1	Chemical Staining and Imaging Methods Have Launched Modern Neuroscience	708
27.4.1	Chemical Control of Genetic Recombination	661	29.3.2	Calcium Imaging Can Be Used to Monitor Neuronal Activity	708
27.4.2	DNA Barcoding Strategies	664	29.3.3	Voltage Sensing Provides a Direct Picture of Neuronal Activity	708
27.5	Summary	665	29.3.4	Neurotransmitters Can Be Sensed with Chemogenetic FRET Sensors	708
	Questions	665	29.3.5	Metals and Gases in the Brain Can Be Sensed with Fluorescent Probes	709
	References	665	29.3.6	Positron Emission Tomography Requires Fast Chemistry	712
<b>28</b>	<b>Chemical Immunology</b>	<b>669</b>	29.3.7	Proximity Ligation Enables Spatially Resolved Mapping of Neural Networks	713
	<i>Matthew E. Griffin, John Teijaro, and Howard C. Hang</i>		29.4	Summary and Outlook	715
28.1	Introduction	669		Questions	715
28.2	Chemical Dissection of Adaptive Immunity	669		References	715
28.3	Generation and Chemical Engineering of Antibodies	672	<b>30</b>	<b>Small-Molecule Drug</b>	
28.4	Antigen Recognition by Immune Cells	673		<b>Discovery</b>	<b>723</b>
28.5	Chemical Innovations for Eliciting and Discovering Antigen-specific Immune Responses	676		<i>Luke L. Lairson</i>	
28.6	Chemical Modulation of Innate Immunity	678	30.1	Introduction	723
28.7	Chemical Dissection of Immunity	682	30.2	Discovery of Chemical Matter	724
28.8	Summary and Future Outlook	685	30.2.1	Target-Based Discovery	724
	Questions	685	30.2.2	HTS-Compatible Assay Formats	725
	References	685	30.2.3	Phenotype-Based Discovery	727
<b>29</b>	<b>Chemical Neurobiology</b>	<b>695</b>	30.2.4	HTS: General Considerations	728
	<i>Johannes Morstein and Dirk Trauner</i>		30.2.5	Drug Repurposing and Serendipity	729
29.1	Introduction	695	30.2.6	Alternative Small-Molecule Discovery Approaches	729
29.2	Actuation	697	30.3	<i>In Vivo</i> Pharmacology: Invention of Drug Candidates and <i>In Vivo</i> Probes	730
29.2.1	Neuropharmacology Has a Storied History	697	30.3.1	Drug Absorption, Distribution, Metabolism, and Excretion	731
29.2.2	Molecular Cloning and Structural Biology Have Revolutionized the Field	697	30.3.1.1	Drug Absorption and Distribution	731
29.2.3	Caged Ligands and Photopharmacology Allow for Optical Control of Neural Activity	699	30.3.1.2	Physicochemical Properties of Drugs	733
29.2.4	Chemogenetics Enables Cell-Specific Neuropharmacology in Brains	701	30.3.1.3	Drug Metabolism and Excretion	734
29.2.5	Tethered Pharmacology Operates on Engineered Receptors or Native Receptors in Genetically Modified Cells	703	30.3.1.4	Pharmacokinetics, Pharmacodynamics, and Biomarkers	737
29.2.6	Tethered Photopharmacology Combines Genetic with Optical Control	704	30.3.2	Medicinal Chemistry	739
29.2.7	Synthetic Photoreceptors Can Be Engineered Through Genetic Code Expansion	705	30.3.3	Drug Toxicity and Human Clinical Trials	743
			30.4	Conclusion	744
				Questions	744
				References	746
				<b>Index</b>	<b>751</b>